Health Care • Biotechnology: Pharmaceutical Preparations
$36.40 ▲ +0.01
(+0.03%)
MKT CAP: $1.45B • VOL: 811.0K
52W L $19 52W H $37
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$31
MEDIAN
$41
MEAN
$42
HIGH
$50
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE PCRX TAPE
PCRX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $44.04 | $41.86 | 2025-02-14 | $33.12 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $45.86 | $42.95 | 2025-02-06 | $34.22 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $41.50 | $40.04 | 2025-01-29 | $34.94 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $37.13 | — | 2025-01-17 | $35.67 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $32.03 | $34.58 | 2025-01-09 | $32.40 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $43.32 | $37.86 | 2024-12-18 | $31.67 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $35.31 | $36.76 | 2024-12-04 | $33.85 | -4.3% | 48% | C |